New Jersey Launches Investigation of Amgen’s Enbrel Marketing Practices
This article was originally published in The Pink Sheet Daily
Executive Summary
State attorney general subpoenas Amgen in the wake of lawsuits filed by former sales reps that allege off-label marketing.
You may also be interested in...
Purdue Feels The Pain With $700 Million Settlement For Misleading OxyContin Promos
Purdue pleads guilty to illegally promoting and selling the painkiller, ending an investigation by the U.S. Attorney’s Office in Virginia.
FDA Change In Bioequivalence Requirements Leads To Downgrade Of Accord’s Generic Tacrolimus
After agency tightened bioequivalence testing recommendations for tacrolimus products post approval, studies found Accord’s generic version of Prograf may deliver higher concentrations, leading agency to downgrade its therapeutic equivalence rating. No problems were found with five other tacrolimus ANDAs.
FTC Set To Take Enforcement Action Against Drugmakers Over Orange Book Patent Listings
Merger reviews could take into account sponsor's Orange Book behavior. FTC's statement does not detail what would make a patent listing 'improper' but the precedents from court cases against various sponsors should offer industry some guideposts.